BX has spent the past week unwinding a textbook crowding-unwind trade — the stock up 7.3%, shorts pulling back sharply, and a freshly post-earnings Street scrambling to catch up on targets — all while the borrow market stays as loose as it has been all year.
The most striking move in the positioning data is the speed of the short retreat. Short interest dropped nearly 14% over the week to 3.3% of the free float, reversing a build that had pushed the count toward 28.4 million shares as recently as August 3. That spike on August 3 now looks like a short-lived crowding event — likely tactical hedges ahead of the Q2 print — that unwound rapidly once the results came in. The covering has been orderly rather than panicked; borrow costs eased more than 20% on the week to 0.36%, and availability is running near 1,700%, meaning the lending pool is abundantly supplied and there is no mechanical squeeze pressure at work. The ORTEX short score has ticked down to 39.5, its lowest reading in the recent ten-day window, consistent with a market that is gradually removing bearish positioning rather than building it.
Options traders are a touch more cautious than usual, which provides the one mild counterweight in the setup. The put/call ratio climbed to 1.38 on Tuesday, roughly 1.6 standard deviations above its 20-day average of 1.31 — not an extreme reading, but the highest single-day print in several weeks. For context, the 52-week PCR range runs from 1.18 to 1.87, so Tuesday's reading sits in the lower half of the defensive zone. The move is consistent with investors buying incremental protection on a stock that has now gained nearly 20% in a month, rather than a genuine bear thesis taking hold.
The Street broadly endorsed the Q2 print, and the direction of analyst revisions tells the story cleanly. Across the firms that updated targets following the July 23 earnings release, upgrades to price targets were universal — RBC lifted to $169, TD Cowen to $145, Goldman Sachs to $127, Barclays to $128, and Oppenheimer to $140 — though the ratings themselves held firm with no upgrades in conviction. Goldman remains at Neutral with a $127 target, which now sits roughly 14% below the current price of $147; that gap is worth flagging as the one structural overhang from a credible house. The mean target across the analyst panel is $142, putting consensus modestly below where the stock trades today. Argus lifted its target to $150 as recently as July 30, keeping a Buy. Bulls point to strong net accrued carry, a diversified investor base, and what the company described as a promising near-term deployment pipeline. Bears note rate sensitivity in the credit and real estate books and the competitive intensity in alternatives fundraising. The dividend factor score ranks in the 95th percentile, a genuine differentiator relative to peers, while EPS surprise sits in the 78th — the earnings beat was real.
The Q2 earnings reaction itself reinforces the positive momentum narrative. The stock jumped 5.8% on the day of the July 23 print and added another 4.3% over the following five sessions — one of the cleaner post-earnings reactions in recent memory for an alternative manager. Peers broadly participated in this week's move: KKR added 6.9% on the day, OWL rose 5.8%, and ARES gained 4.0%, suggesting the sector tailwind is real rather than BX-specific. CG was the outlier, losing 4.5% on the week — a divergence that may reflect Carlyle-specific dynamics rather than a read-through to the group.
With the next earnings date on October 16, the near-term focus shifts to whether Blackstone can sustain Q3 deployment momentum and whether credit spreads remain supportive enough to protect the carry book — two variables that Goldman's cautious Neutral rating implicitly flags as unresolved.
See the live data behind this article on ORTEX.
Open BX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
